Therapeutic Approaches to Obesity

Prevention

Opinion statement

Obesity in the United States has become a public health crisis, with one third of the US population having a body mass index ≥30 kg/m2. Given the profound impact of obesity on cardiovascular disease (CVD), studies of lifestyle modification, pharmacotherapy, and surgical interventions must be reappraised to better define the roles of these approaches in preventing cardiovascular events. Recent clinical trials have attempted to quell the debate over macronutrient composition versus caloric restriction in the dietary approach to weight loss. Our interpretation of these results is that caloric reduction and adherence to diets are of greater consequence than the particular dietary content for weight reduction. For cardiovascular risk factor modification, however, specific macronutrient composition of the diet may have additional impact outside weight loss, although the ultimate relationship between various dietary macronutrients and clinical cardiovascular outcomes is unclear. Although pharmacotherapy has been used for decades to treat obesity, there currently are limited options and recurrent cautionary tales; therefore, we use these agents sparingly. Sibutramine, one of only two medications approved by the US Food and Drug Administration for the long-term treatment of obesity, recently came under intense scrutiny because of a possible increase in cardiovascular events, and it now is contraindicated in patients with established CVD. Orlistat and its over-the-counter form, Alli (GlaxoSmithKline, Research Triangle Park, NC), can induce modest weight loss but frequently are not tolerated because of unpleasant gastrointestinal side effects. Fortunately, there are new medications in phase 3 clinical trials that hold promise as potential alternatives for obesity treatment. Finally, bariatric surgery for morbid obesity refractory to lifestyle interventions has become considerably more common. Surgery can effectively reduce body weight and treat cardiovascular risk factors, particularly diabetes, with acceptable complication rates and should be considered a viable option for appropriate patients. Ongoing clinical trials will clarify the impact of bariatric surgery on cardiovascular events and mortality, as well as the role of surgery as a treatment option that may be considered earlier than currently recommended.

Notes

Disclosure

Dr. Khera has been a consultant to Daiichi-Sankyo. No other potential conflicts of interest relevant to this article were reported.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance•• Of major importance

  1. 1.
    Flegal KM, Carroll MD, Ogden CL, Curtin CR: Prevalence and trends in obesity among US adults, 1999–2008. JAMA 2010, 303:235–241.CrossRefPubMedGoogle Scholar
  2. 2.
    Flegal KM, Graubard BI, Williamson DF, Gail MH: Excess deaths associated with underweight, overweight, and obesity. JAMA 2005, 293:1861–1867.CrossRefPubMedGoogle Scholar
  3. 3.
    Poirier P, Giles TD, Bray GA, et al.: Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113:898–918.CrossRefPubMedGoogle Scholar
  4. 4.
    Khera A, Vega GL, Das SR, et al.: Sex differences in the relationship between C-reactive protein and body fat. J Clin Endocrinol Metab 2009, 94:3251–3158.CrossRefPubMedGoogle Scholar
  5. 5.
    Yusuf S, Hawken S, Ounpuu S, et al.: Obesity and the risk of myocardial infarction in 27, 000 participants from 52 countries: a case-control study. Lancet 2005, 366:1640–1649.CrossRefPubMedGoogle Scholar
  6. 6.
    Flegal KM, Graubard BI, Williamson DF, Gail MH: Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007, 298:2028–2037.CrossRefPubMedGoogle Scholar
  7. 7.
    Anand SS, Islam S, Rosengren A, et al.: Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 2008, 29:932–940.CrossRefPubMedGoogle Scholar
  8. 8.
    See R, Abdullah SM, McGuire DK, et al.: The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study. J Am Coll Cardiol 2007, 50:752–759.CrossRefPubMedGoogle Scholar
  9. 9.
    Arnlov J, Ingelsson E, Sundstrom J, Lind L: Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010, 121:230–236.CrossRefPubMedGoogle Scholar
  10. 10.
    Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report National Institutes of Health. Obes Res 1998, 6(Suppl 2):51S–209S.Google Scholar
  11. 11.
    Gardner CD, Kiazand A, Alhassan S, et al.: Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z Weight Loss Study: a randomized trial. JAMA 2007, 297:969–977.CrossRefPubMedGoogle Scholar
  12. 12.
    Shai I, Schwarzfuchs D, Henkin Y, et al.: Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008, 359:229–241.CrossRefPubMedGoogle Scholar
  13. 13.••
    Sacks FM, Bray GA, Carey VJ, et al.: Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009, 360:859–873.CrossRefPubMedGoogle Scholar
  14. 14.••
    Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, Brancati FL, et al.: Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007, 30:1374–1383.CrossRefPubMedGoogle Scholar
  15. 15.
    Wing RR: Reduction in weight and cardiovascular disease (CVD) risk factors in subjects with type 2 diabetes (T2DM): four-year results of Look AHEAD [abstract]. Obesity 2009, 17:S49.CrossRefGoogle Scholar
  16. 16.
    Wadden TA, Wing RR, Ryan DH, Neiberg R: Four-year weight losses in individuals with type 2 diabetes in the Look AHEAD study [abstract]. Obesity 2009, 17:S76.CrossRefGoogle Scholar
  17. 17.
    A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-Agent Constituents for Treatment of Obesity in Adults. Available at http://www.clinicaltrials.gov. Clinical trial #NCT00563368. Accessed December 2009.
  18. 18.
    Garvey WT, Troupin B, Tam P, et al.: One-year treatment with low dose VI-0521 in type 2 diabetes demonstrates sustained weight loss and continuous glycemic benefit [abstract]. Obesity 2009, 17:S52.Google Scholar
  19. 19.
    Online Pharmacy. Available at htpp://www.drugstore.com. Accessed January 2010.
  20. 20.
    Wadden TA, Berkowitz RI, Wombie LG, et al.: Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005, 353:2111–2120.CrossRefPubMedGoogle Scholar
  21. 21.
    Padwal RS, Majumdar SR: Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007, 369:71–77.CrossRefPubMedGoogle Scholar
  22. 22.
    Meridia (Sibutramine Hydrochloride): Early Communication About an Ongoing Safety Review. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm191655.htm. Accessed November 2009.
  23. 23.
    Meridia (Sibutramine Hydrochloride): Follow-Up to an Early Communication About an Ongoing Safety Review. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198221.htm. Accessed January 2010.
  24. 24.
    Padwal R, Li SK, Lau DC: Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2003, CD004094.Google Scholar
  25. 25.
    Hutton B, Fergusson D: Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 2004, 80:1461–1468.PubMedGoogle Scholar
  26. 26.
    Smith SR, Prosser WA, Donahue DJ, et al.: Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2009, 17:494–503.CrossRefGoogle Scholar
  27. 27.
    Anderson CM, Smith SR, Sanchez M, et al.: Lorcaserin treatment was associated with improvements in cardiovascular risk factors and weight loss in the BLOOM trial [abstract]. Obesity 2009, 17:S52.Google Scholar
  28. 28.
    Barnett AH: New treatments in type 2 diabetes: a focus on the incretin-based therapies. Clin Endocrinol 2009, 70:343–353.CrossRefGoogle Scholar
  29. 29.
    Astrup A, Rossner S, Van Gaal L, et al.: Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374:1606–1616.CrossRefPubMedGoogle Scholar
  30. 30.
    Astrup A: Al Hakim M, Savolainen MJ, et al.: Treatment with liraglutide, a once-daily human GLP-1 analog, for 52 weeks reduces weight and waist circumference: a randomized placebo-controlled trial [abstract]. Obesity 2009, 17:S51.Google Scholar
  31. 31.
    Robinson MK: Surgical treatment of obesity—weighing the facts. N Engl J Med 2009, 361:520–521.CrossRefPubMedGoogle Scholar
  32. 32.
    Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 1992, 55:615S–619S.Google Scholar
  33. 33.
    Buchwald H, Avidor Y, Braunwald E, et al.: Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292:1724–1737.CrossRefPubMedGoogle Scholar
  34. 34.
    Sjostrom L, Lindroos AK, Peltonen M, et al.: Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683–2693.CrossRefPubMedGoogle Scholar
  35. 35.
    Buchwald H, Estok R, Fahrbach K, et al.: Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009, 122:248–256.e5.Google Scholar
  36. 36.
    Dixon JB, O’Brien PE, Playfair J, et al.: Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008, 299:316–323.CrossRefPubMedGoogle Scholar
  37. 37.••
    Adams TD, Gress RE, Smith SC, et al.: Long-term mortality after gastric bypass surgery. N Engl J Med 2007, 357:753–761.CrossRefPubMedGoogle Scholar
  38. 38.••
    Sjostrom L, Narbro K, Sjostrom CD, et al.: Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007, 357:741–752.CrossRefPubMedGoogle Scholar
  39. 39.
    Flum DR, Belle SH, King WC, et al.: Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009, 361:445–454.CrossRefPubMedGoogle Scholar
  40. 40.
    Long Term Effects of Bariatric Surgery (LABS-2). Available at http://www.clinicaltrials.gov. Clinical trial #NCT00465829. Accessed December 2009.
  41. 41.
    National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK): Bariatric Surgery for Severe Obesity. Available at http://win.niddk.nih.gov/publications/gastric.htm. Accessed November 2009.

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.University of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations